---
title: "Aligos Therapeutics (ALGS) Gets a Buy from H.C. Wainwright"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283864894.md"
description: "H.C. Wainwright analyst Patrick Trucchio has reiterated a Buy rating on Aligos Therapeutics (ALGS) with a price target of $50.00. Trucchio, a 5-star analyst with a 30.0% average return and 53.97% success rate, focuses on the Healthcare sector. Previously, Piper Sandler also maintained a Buy rating on ALGS with a price target of $175.00."
datetime: "2026-04-23T15:55:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283864894.md)
  - [en](https://longbridge.com/en/news/283864894.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283864894.md)
---

# Aligos Therapeutics (ALGS) Gets a Buy from H.C. Wainwright

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Aligos Therapeutics, with a price target of $50.00.

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Trucchio is a 5-star analyst with an average return of 30.0% and a 53.97% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Atai Beckley N.V., Definium Therapeutics, and Immunocore Holdings.

In a report released on April 15, Piper Sandler also maintained a Buy rating on the stock with a $175.00 price target.

### Related Stocks

- [ALGS.US](https://longbridge.com/en/quote/ALGS.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ATAI.US](https://longbridge.com/en/quote/ATAI.US.md)
- [IMCR.US](https://longbridge.com/en/quote/IMCR.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 | ALGS Stock News](https://longbridge.com/en/news/286205055.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)